文献速递淋巴瘤

胸腺和活化调节趋化因子(TARC)作为儿童霍奇金淋巴瘤治疗反应标志物:一项先导研究

Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
PubMed 文献 · Br J Haematol · 2022-09-20

这项多中心前瞻性研究在99例儿童经典型霍奇金淋巴瘤(cHL)患者中,于每周期化疗前检测血浆TARC水平,并与中期及治疗结束时的缓解状态关联。结果显示,诊断时96%患者TARC升高,化疗一周期后显著下降,但中期评估时与PET结果无关;治疗结束时进展患者TARC显著高于完全缓解者。研究表明血浆TARC是治疗结束时的有用反应标志物,而非前两周期化疗后的中期分析标志物。

要点

  • 诊断时96%儿童cHL患者血浆TARC水平升高。
  • 化疗一周期后TARC较基线显著下降(p < 0.01)。
  • 治疗结束时进展患者TARC中位数1.226 pg/ml,显著高于完全缓解者90 pg/ml(p < 0.001)。

核心结论

  • 在儿童cHL患者中,血浆TARC是治疗结束时的有用反应标志物,但不是前两周期化疗后中期分析时的标志物。
  • 需要进一步研究探讨TARC作为长期无进展生存标志物的价值。

研究设计与样本

  • 多中心前瞻性先导研究,纳入99例儿童经典型霍奇金淋巴瘤患者。
  • 于每周期化疗前采用酶联免疫吸附试验检测血浆TARC水平,并与中期及治疗结束时缓解状态关联。

主要发现

  • 诊断时96%患者TARC水平升高。
  • 化疗一周期后血浆TARC较基线显著下降(p < 0.01 vs. 基线)。
  • 中期评估时TARC水平按PET结果无差异(p = 0.31)。
  • 治疗结束时,3例进展患者血浆TARC中位数1.226 pg/ml,显著高于完全缓解者90 pg/ml(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究探讨TARC作为长期无进展生存标志物的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker in adult patients with cHL is thymus and activation-regulated chemokine (TARC). We investigated TARC as marker for interim and end-of-treatment response in paediatric cHL. In this multicentre prospective study, TARC levels were measured among 99 paediatric patients with cHL before each cycle of chemotherapy and were linked with interim and end-of-treatment remission status. TARC levels were measured by enzyme-linked immunosorbent assay. At diagnosis, TARC levels were elevated in 96% of patients. Plasma TARC levels declined significantly after one cycle of chemotherapy (p < 0.01 vs. baseline) but did not differ at interim assessment by positron emission tomography (p = 0.31). In contrast, median plasma TARC at end of treatment was significantly higher in three patients with progressive disease compared to those in complete remission (1.226 vs. 90 pg/ml; p < 0.001). We demonstrate that, in paediatric patients, plasma TARC is a valuable response marker at end-of-treatment, but not at interim analysis after the first two chemotherapy cycles. Further research is necessary to investigate TARC as marker for long-term progression free survival.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zijtregtop EAM, Diez C, Zwaan CM, et al. Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study. Br J Haematol. 2022. PMID: 36128637. doi:10.1111/bjh.18473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。